Why Leukemia Isn’t Like Other Cancers

Gloved hand holding a blood sample tube in a lab rack — Photo: Roman Zaiets / Shutterstock

Blood cancer doesn’t behave like the tumors most people picture when they hear the word “cancer,” and that difference is changing how doctors fight it.

Story Snapshot

Leukemia begins in blood cells, not solid organs, so surgery to remove a tumor is not an option.
Doctors now test leukemia cells for specific genetic changes before choosing a treatment plan.
Targeted drugs attack those genetic flaws directly, often letting patients skip harsh chemotherapy.
Blood cancers have led the way in genetic testing for decades, ahead of many solid tumor cancers.

Why Leukemia Plays By Different Rules

Leukemia forms when blood cells pick up mutations in their DNA, causing them to grow out of control. Unlike a tumor in the lung or colon, leukemia cells circulate through the bloodstream and bone marrow. There is no mass to remove with a scalpel. That single fact forces doctors to think differently about treatment from day one, relying on blood and marrow samples instead of imaging scans to track the disease.

Doctor Mahmoud Aljurf Arana Yi, a Mayo Clinic hematologist, explains that researchers are getting better at spotting the exact genetic changes driving a patient’s leukemia. That information does more than confirm a diagnosis. It tells doctors which drugs are likely to work. “This allows us to use targeted medicines, immune-based therapies, sometimes with less traditional chemotherapy or chemo-free regimen,” Yi says.

Genetic Testing Now Drives Treatment Choices

Mayo Clinic’s own patient guidance backs this up. Leukemia cells get tested for specific abnormalities before doctors decide whether targeted therapy will help. These targeted drugs go after the exact flaw inside the cancer cell, causing it to die, while sparing more healthy tissue than older chemotherapy drugs typically do.

Getting the right diagnosis matters just as much as picking the right drug. Mayo Clinic notes that different leukemia types need different treatments entirely, and some therapies only work for patients carrying certain genetic markers. That is why molecular testing has become a standard step, not an optional extra, right after diagnosis.

Acute Myeloid Leukemia Shows How Far Testing Has Come

Acute myeloid leukemia offers a clear example of how much progress has happened recently. “We now understand that almost everybody with acute myeloid leukemia will have some genetic abnormality in the cells,” one Mayo Clinic cancer expert notes, describing massive treatment advances over the last five to seven years. Mayo Clinic Laboratories now runs gene panels checking for specific mutations like FLT3 and IDH1 to help guide therapy choices for these patients.

Chronic lymphocytic leukemia follows a similar path. Doctors use a specialized test to hunt for genetic changes in the cancer cells, and those results directly shape which drugs a patient receives. This approach lets care teams individualize treatment instead of applying one chemotherapy plan to every patient walking through the door.

Blood Cancers Led The Way On Precision Medicine

Blood cancers were the original proving ground for this genetic approach to treatment, years before it became common in solid tumors. Chronic myelogenous leukemia became the textbook case after a drug called imatinib showed that targeting a single genetic driver could transform outcomes for patients. Genetic testing has been a routine part of blood cancer care for decades, well ahead of many solid tumor fields still catching up.

That head start still shows today. Reviews of cancer genetics note that gene-targeted approvals for acute myeloid leukemia already exist, covering mutations like FLT3 and IDH1/IDH2, giving doctors approved drugs matched to specific genetic profiles. Solid tumor research, including newer cell therapies, continues working to catch up to that level of targeted precision.

None of this means every leukemia patient gets a chemo-free path or a guaranteed match to a targeted drug. Testing results and available therapies still vary by leukemia type and individual case. What has changed is the starting point. Doctors now begin with a genetic map of the cancer rather than a one-size-fits-all chemotherapy plan, giving patients a more tailored shot at treatment that actually fits their disease.